Ozempic acceleration buoys Novo Nordisk, and threatens LillySolid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat Share XOzempic acceleration buoys Novo Nordisk, and threatens Lillyhttps://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/
Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challengeEli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but Share XLilly’s diabetes med Trulicity shrugs off Novo Nordisk challengehttps://pharmaphorum.com/news/lillys-diabetes-med-trulicity-shrugs-off-novo-nordisk-challenge/
Novartis results show Zolgensma early growth wasn’t a flukeNovartis’ bumper crop of new product launches in 2019 helped it post 9% sales growth in the fourth Share XNovartis results show Zolgensma early growth wasn’t a flukehttps://pharmaphorum.com/news/novartis-results-show-zolgensmas-early-growth-wasnt-a-fluke/
Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
Vyndaqel romps away in US, spurring earnings hike from PfizerPfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its Share XVyndaqel romps away in US, spurring earnings hike from Pfizerhttps://pharmaphorum.com/news/vyndaqel-romps-away-in-us-spurring-earnings-hike-from-pfizer/
Cancer update buoys Amgen despite Q2 sales fallAmgen’s second quarter revenues were down 3% as competition pegged back its off-patent drugs Sensipar and Neulasta, but Share XCancer update buoys Amgen despite Q2 sales fallhttps://pharmaphorum.com/news/cancer-update-buoys-amgen-despite-q2-sales-fall/
J&J warns generics will bite its pharma unit in the second halfJohnson & Johnson has kicked off the interim results season with a warning that low-cost generic and biosimilar Share XJ&J warns generics will bite its pharma unit in the second halfhttps://pharmaphorum.com/news/jj-warns-generics-will-bite-its-pharma-unit-in-the-second-half/
Sanofi expects growth as rare disease drugs boost earningsSanofi’s strategy of betting on new drugs and biotech acquisitions seems to be paying off, as the company Share XSanofi expects growth as rare disease drugs boost earningshttps://pharmaphorum.com/news/sanofi-expects-growth-as-rare-disease-drugs-boost-earnings/
